{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:59:13Z","timestamp":1792083553989,"version":"4.4.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100020084","name":"Guangzhou Municipal Science and Technology Bureau","doi-asserted-by":"publisher","award":["SL2024A04J00706"],"award-info":[{"award-number":["SL2024A04J00706"]}],"id":[{"id":"10.13039\/501100020084","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013262","name":"State Key Laboratory of Respiratory Disease","doi-asserted-by":"publisher","award":["SKLRD-OP-202402"],"award-info":[{"award-number":["SKLRD-OP-202402"]}],"id":[{"id":"10.13039\/100013262","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013262","name":"State Key Laboratory of Respiratory Disease","doi-asserted-by":"publisher","award":["SKLRD-Z-202706"],"award-info":[{"award-number":["SKLRD-Z-202706"]}],"id":[{"id":"10.13039\/100013262","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2027,2]]},"DOI":"10.1016\/j.cca.2026.121296","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:17:55Z","timestamp":1787584675000},"page":"121296","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Joint mixture effects and population attributable burden of ANA\/ENA panels in connective tissue disease\u2013associated interstitial lung disease"],"prefix":"10.1016","volume":"593","author":[{"given":"Kaixin","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengtao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhangkai J.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoqing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.cca.2026.121296_bb0005","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1164\/rccm.200701-044OC","article-title":"Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003","volume":"176","author":"Olson","year":"2007","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"9","key":"10.1016\/j.cca.2026.121296_bb0010","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"18","key":"10.1016\/j.cca.2026.121296_bb0015","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.cca.2026.121296_bb0020","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.cca.2026.121296_bb0025","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir. Med."},{"issue":"9842","key":"10.1016\/j.cca.2026.121296_bb0030","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0140-6736(12)61079-4","article-title":"Interstitial lung disease in connective tissue disorders","volume":"380","author":"Fischer","year":"2012","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.cca.2026.121296_bb0035","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.rmed.2009.02.009","article-title":"Ascertainment of collagen vascular disease in patients presenting with interstitial lung disease","volume":"103","author":"Mittoo","year":"2009","journal-title":"Respir. Med."},{"issue":"10","key":"10.1016\/j.cca.2026.121296_bb0040","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1164\/rccm.201903-0486OC","article-title":"Tracking impact of interstitial lung disease in systemic sclerosis in a complete nationwide cohort","volume":"200","author":"Hoffmann-Vold","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"6","key":"10.1016\/j.cca.2026.121296_bb0045","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1164\/rccm.201903-0563CI","article-title":"Etiology, risk factors, and biomarkers in systemic sclerosis with interstitial lung disease","volume":"201","author":"Khanna","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.cca.2026.121296_bb0050","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1212\/WNL.0000000000009727","article-title":"Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: study of 121 cases","volume":"95","author":"Allenbach","year":"2020","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.cca.2026.121296_bb0055","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.semarthrit.2016.03.011","article-title":"Clinical manifestations and long-term outcome of anti-Jo-1 antisynthetase patients in a large cohort of Spanish patients from the GEAS-IIM Group","volume":"46","author":"Trallero-Aragu\u00e1s","year":"2016","journal-title":"Semin. Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.cca.2026.121296_bb0060","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","article-title":"Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial","volume":"11","author":"Maher","year":"2023","journal-title":"Lancet Respir. Med."},{"issue":"6","key":"10.1016\/j.cca.2026.121296_bb0065","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias","volume":"188","author":"Travis","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"4","key":"10.1016\/j.cca.2026.121296_bb0070","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1183\/13993003.00150-2015","article-title":"An official European Respiratory Society\/American Thoracic Society research statement: interstitial pneumonia with autoimmune features","volume":"46","author":"Fischer","year":"2015","journal-title":"Eur. Respir. J."},{"issue":"6","key":"10.1016\/j.cca.2026.121296_bb0075","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1183\/13993003.01565-2015","article-title":"Characterization of patients with interstitial pneumonia with autoimmune features","volume":"47","author":"Oldham","year":"2016","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.cca.2026.121296_bb0080","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.chest.2017.03.004","article-title":"Idiopathic interstitial pneumonia associated with autoantibodies: a large case series followed over one year","volume":"152","author":"Collins","year":"2017","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.cca.2026.121296_bb0085","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/resp.12588","article-title":"Idiopathic interstitial pneumonias with connective tissue diseases features: a review","volume":"21","author":"Cottin","year":"2016","journal-title":"Respirology"},{"issue":"7","key":"10.1016\/j.cca.2026.121296_bb0090","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1136\/annrheumdis-2018-214436","article-title":"Clinical relevance of HEp-2 indirect immunofluorescent patterns: the international consensus on ANA patterns (ICAP) perspective","volume":"78","author":"Damoiseaux","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"9","key":"10.1016\/j.cca.2026.121296_bb0095","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1002\/art.1780400909","article-title":"Range of antinuclear antibodies in \u201chealthy\u201d individuals","volume":"40","author":"Tan","year":"1997","journal-title":"Arthritis Rheum."},{"issue":"12","key":"10.1016\/j.cca.2026.121296_bb0100","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41584-020-00522-w","article-title":"Understanding and interpreting antinuclear antibody tests in systemic rheumatic diseases","volume":"16","author":"Bossuyt","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"issue":"10","key":"10.1016\/j.cca.2026.121296_bb0105","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1289\/ehp.1206185","article-title":"Short-term exposure to particulate matter constituents and mortality in a national study of U.S. urban communities","volume":"121","author":"Krall","year":"2013","journal-title":"Environ. Health Perspect."},{"issue":"1","key":"10.1016\/j.cca.2026.121296_bb0110","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s13253-014-0180-3","article-title":"Characterization of weighted quantile sum regression for highly correlated data in a risk analysis setting","volume":"20","author":"Carrico","year":"2015","journal-title":"J. Agric. Biol. Environ. Stat."},{"issue":"4","key":"10.1016\/j.cca.2026.121296_bb0115","doi-asserted-by":"crossref","DOI":"10.1289\/EHP5838","article-title":"A quantile-based g-computation approach to addressing the effects of exposure mixtures","volume":"128","author":"Keil","year":"2020","journal-title":"Environ. Health Perspect."},{"issue":"4","key":"10.1016\/j.cca.2026.121296_bb0120","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.cca.2026.121296_bb0125","article-title":"Population attributable fraction","volume":"360","author":"Mansournia","year":"2018","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.cca.2026.121296_bb0130","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.autrev.2009.02.010","article-title":"Latest update on the Ro\/SS-A autoantibody system","volume":"8","author":"Schulte-Pelkum","year":"2009","journal-title":"Autoimmun. Rev."},{"issue":"7","key":"10.1016\/j.cca.2026.121296_bb0135","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1136\/annrheumdis-2018-215004","article-title":"Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis","volume":"78","author":"Sabbagh","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"8","key":"10.1016\/j.cca.2026.121296_bb0140","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.3899\/jrheum.150844","article-title":"Rituximab in the treatment of Jo1 antibody-associated antisynthetase syndrome: anti-Ro52 positivity as a marker for severity and treatment response","volume":"43","author":"Bauhammer","year":"2016","journal-title":"J. Rheumatol."},{"issue":"3","key":"10.1016\/j.cca.2026.121296_bb0145","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/08916930600623791","article-title":"In patients with antisynthetase syndrome the occurrence of anti-Ro\/SSA antibodies causes a more severe interstitial lung disease","volume":"39","author":"La Corte","year":"2006","journal-title":"Autoimmunity"},{"issue":"3","key":"10.1016\/j.cca.2026.121296_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.103013","article-title":"An updated review of anti-Ro52 (TRIM21) antibodies impact in connective tissue diseases clinical management","volume":"21","author":"Decker","year":"2022","journal-title":"Autoimmun. Rev."},{"issue":"3","key":"10.1016\/j.cca.2026.121296_bb0155","doi-asserted-by":"crossref","first-page":"865","DOI":"10.2307\/2532206","article-title":"Maximum likelihood estimation of the attributable fraction from logistic models","volume":"49","author":"Greenland","year":"1993","journal-title":"Biometrics"},{"issue":"8","key":"10.1016\/j.cca.2026.121296_bb0160","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1084\/jem.20090585","article-title":"Loss of the lupus autoantigen Ro52\/Trim21 induces tissue inflammation and systemic autoimmunity by disregulating the IL-23\u2013Th17 pathway","volume":"206","author":"Espinosa","year":"2009","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.cca.2026.121296_bb0165","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.4049\/jimmunol.181.3.1780","article-title":"The E3 ubiquitin ligase Ro52 negatively regulates IFN-\u03b2 production post-pathogen recognition by polyubiquitin-mediated degradation of IRF3","volume":"181","author":"Higgs","year":"2008","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.cca.2026.121296_bb0170","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/art.10760","article-title":"A comparison between anti-Th\/to- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement","volume":"48","author":"Mitri","year":"2003","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.cca.2026.121296_bb0175","doi-asserted-by":"crossref","first-page":"R22","DOI":"10.1186\/ar2614","article-title":"Antibodies against PM\/Scl-75 and PM\/Scl-100 are independent markers for different subsets of systemic sclerosis patients","volume":"11","author":"Hanke","year":"2009","journal-title":"Arthritis Res. Ther."},{"issue":"4","key":"10.1016\/j.cca.2026.121296_bb0180","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/art.24409","article-title":"Anti-U3 RNP autoantibodies in systemic sclerosis","volume":"60","author":"Aggarwal","year":"2009","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.cca.2026.121296_bb0185","first-page":"202","article-title":"Scleroderma (systemic sclerosis): classification, subsets and pathogenesis","volume":"15","author":"LeRoy","year":"1988","journal-title":"J. Rheumatol."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000989812600478X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000989812600478X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:27:59Z","timestamp":1792081679000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000989812600478X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,2]]},"references-count":37,"alternative-id":["S000989812600478X"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2026.121296","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2027,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Joint mixture effects and population attributable burden of ANA\/ENA panels in connective tissue disease\u2013associated interstitial lung disease","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2026.121296","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"121296"}}